Inflammation, DHT, and the Biochemical Cascade of Hair Loss:
A Scientific Overview

Hair loss, or alopecia, is a prevalent condition affecting millions worldwide, with significant variations across age, gender, and ethnicity. In the United States, androgenetic alopecia (AGA), commonly known as male or female pattern baldness, impacts approximately 50 million men and 30 million women. The onset of AGA can occur as early as a person's teens, with risk increasing with age; notably, over 50% of men aged 50 and above experience some degree of hair loss.[1] In women, hair loss is more likely after menopause. Globally, the prevalence of AGA varies, but up to 80% of men and 50% of women are affected in the course of their life…Recent advances in ECM technology, have shown promise in supporting the cells at the wound bed to move through the inflammation phase (often associated with pain, swelling, and redness) most rapidly, and through the proliferation phase where structural healing occurs. [12] Reyagel by Fettech has adapted their MTP ECM into an easy to use sterile gel that can be applied directly to wounds as an FDA cleared medical device, and FUE follicular units can be dipped in the gel to support engraftment, attenuating inflammation, and providing growth factors and exosomes as well.